Outcomes of a 42-day course of molnupiravir in cats with feline infectious peritonitis: a prospective descriptive study.
- 1Veterinary Specialists Emergency Center, Saitama 333-0823, Japan.
Abstract
Background
Antiviral therapy for cats with feline infectious peritonitis (FIP) has traditionally been administered for 84 days, although the optimal duration of molnupiravir treatment remains unknown.Hypothesis/objectives
To evaluate the efficacy of a 42-day course of molnupiravir, orally (PO), for naturally occurring FIP in cats.Animals
Nineteen client-owned cats with newly diagnosed FIP.Methods
Prospective pilot study. Cats received molnupiravir, PO, q12h for 42 days at a median dosage of 11.5 mg/kg (IQR, 10.2-12.5 mg/kg). Cats with ocular or neurological involvement were excluded. Clinical assessments were performed during treatment and for 6 months after treatment cessation.Results
Nineteen cats were enrolled. Two cats failed to complete treatment because of death or persistent clinical signs. Fourteen of 19 cats (74%; 95% CI, 49-91) achieved sustained remission on an intention-to-treat basis. Each non-completer failed on day 5 or 10, respectively, within a window common to 42- and 84-day protocols, and therefore do not inform the question of treatment duration; among the 17 cats reaching day 42, 14 (82%; 95% CI, 57-96) remained in remission for at least 6 months. Three cats relapsed after treatment cessation; all responded to retreatment with molnupiravir at the same dosage extended to 84 days.Conclusions and clinical importance
This prospective study suggests that a shortened course of molnupiravir is feasible in selected cats with non-ocular, non-neurological FIP.Abstract (japanese)
: (FIP) にするウイルスは 84 されてきたが、モルヌピラビルのなはらかではない。 : FIP のにするモルヌピラビル 42 のをすること。 : たに FIP とされた19。 : きパイロット。モルヌピラビルを 12 ごとに 42 した。のは 11.5 mg/kg (、 10.2-12.5 mg/kg) であった。またはをするはした。および 6 か、をった。 : 19 をした。 2 はまたはのによりをできなかった。 Intention-to-treat では 19 14 (74 %； 95% 、 49-91) がをした。の 2 はそれぞれ5および10にとなり、いずれも 42 および 84 のプロトコルにするであったため、のにはしなかった。 42 までをした 17 のうち 14 (82% ； 95% 、 57-96) はなくとも 6 かをした。 3 はにしたが、がのモルヌピラビルによる 84 のにした。 および: きパイロットのから、およびをわない FIP のでは、モルヌピラビルのがであるがされた。.
Related
- A tri-modular feline infectious peritonitis virus nanoparticle vaccine confers complete protection in female cats without detectable antibody-dependent enhancement
- Development and Application of a Dual-Fluorescent Reporter Assay for Feline Infectious Peritonitis Virus RNA-Dependent RNA Polymerase Inhibitor Screening.
- Clinical features of ROHHAD syndrome and treatment outcomes following rituximab therapy: a descriptive case series of Chinese children
- Digital health technologies and measurable management outcomes in primary care: A systematic review, descriptive quantitative synthesis, and temporal sensitivity analysis
- The effect of intraperitoneal St. John's Wort oil (Hypericum perforatum) in an experimental peritonitis model.
BibTeX
@article{hishinuma2026outcomes,
title = {{Outcomes of a 42-day course of molnupiravir in cats with feline infectious peritonitis: a prospective descriptive study.}},
author = {Kenta Hishinuma and Akiko Inoue and Kenjiro Fukushima and Masahiko Sato},
journal = {Journal of veterinary internal medicine},
year = {2026},
month = sep,
doi = {10.1093/jvimsj/aalag268},
url = {https://europepmc.org/article/MED/42949438},
note = {CC BY},
}
RIS
TY - JOUR
TI - Outcomes of a 42-day course of molnupiravir in cats with feline infectious peritonitis: a prospective descriptive study.
AU - Kenta Hishinuma
AU - Akiko Inoue
AU - Kenjiro Fukushima
AU - Masahiko Sato
PY - 2026
DA - 2026/09/01
JO - Journal of veterinary internal medicine
DO - 10.1093/jvimsj/aalag268
UR - https://europepmc.org/article/MED/42949438
AB - Background Antiviral therapy for cats with feline infectious peritonitis (FIP) has traditionally been administered for 84 days, although the optimal duration of molnupiravir treatment remains unknown.Hypothesis/objectives To evaluate the efficacy of a 42-day course of molnupiravir, orally (PO), for naturally occurring FIP in cats.Animals Nineteen client-owned cats with newly diagnosed FIP.Methods Prospective pilot study. Cats received molnupiravir, PO, q12h for 42 days at a median dosage of 11.5 mg/kg (IQR, 10.2-12.5 mg/kg). Cats with ocular or neurological involvement were excluded. Clinical assessments were performed during treatment and for 6 months after treatment cessation.Results Nineteen cats were enrolled. Two cats failed to complete treatment because of death or persistent clinical signs. Fourteen of 19 cats (74%; 95% CI, 49-91) achieved sustained remission on an intention-to-treat basis. Each non-completer failed on day 5 or 10, respectively, within a window common to 42- and 84-day protocols, and therefore do not inform the question of treatment duration; among the 17 cats reaching day 42, 14 (82%; 95% CI, 57-96) remained in remission for at least 6 months. Three cats relapsed after treatment cessation; all responded to retreatment with molnupiravir at the same dosage extended to 84 days.Conclusions and clinical importance This prospective study suggests that a shortened course of molnupiravir is feasible in selected cats with non-ocular, non-neurological FIP.Abstract (japanese) : (FIP) にするウイルスは 84 されてきたが、モルヌピラビルのなはらかではない。 : FIP のにするモルヌピラビル 42 のをすること。 : たに FIP とされた19。 : きパイロット。モルヌピラビルを 12 ごとに 42 した。のは 11.5 mg/kg (、 10.2-12.5 mg/kg) であった。またはをするはした。および 6 か、をった。 : 19 をした。 2 はまたはのによりをできなかった。 Intention-to-treat では 19 14 (74 %； 95% 、 49-91) がをした。の 2 はそれぞれ5および10にとなり、いずれも 42 および 84 のプロトコルにするであったため、のにはしなかった。 42 までをした 17 のうち 14 (82% ； 95% 、 57-96) はなくとも 6 かをした。 3 はにしたが、がのモルヌピラビルによる 84 のにした。 および: きパイロットのから、およびをわない FIP のでは、モルヌピラビルのがであるがされた。.
SN - 0891-6640
SN - 1939-1676
ER -